Immatics N.V.
Immatics N.V. (IMTX): 7 pipeline candidates · 1 upcoming catalyst · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
0% dilution
Lead: Phase 3
7 candidates
1 upcoming, next in ~1931d
N/A
A transparent, data-derived signal for Immatics N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.3B
Cash
$345.9M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| ima 401 | Phase 1 |
| ima203 | Phase 3 |
| ima203 product | Phase 3 |
| ima203 product- flat dose | Phase 3 |
| ima203cd8 product | Phase 3 |
| ima401 | Phase 1 |
| lifileucel | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
79
Total value held
$809.9M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 20,766,912 | $204.3M |
| rtw investments, lp | 12,869,340 | $126.6M |
| suvretta capital management, llc | 11,190,129 | $110.1M |
| baker bros. advisors lp | 10,916,693 | $107.4M |
| toronto dominion bank | 7,436,342 | $73.2M |
| morgan stanley | 2,149,082 | $21.1M |
| woodline partners lp | 2,001,194 | $19.7M |
| citadel advisors llc | 1,874,563 | $18.4M |
| wellington management group llp | 1,561,892 | $15.4M |
| point72 asset management, l.p. | 1,493,800 | $14.7M |
Showing top 10 of 79 institutional holders of Immatics N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Immatics N.V.'s pipeline?
Immatics N.V. (IMTX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Immatics N.V.'s lead drug candidate?
Immatics N.V.'s most advanced tracked candidate is ima 401 (Phase 1) for Refractory Cancer.
What is Immatics N.V.'s next catalyst?
Immatics N.V.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clin" — expected October 1, 2031.
What is Immatics N.V.'s market capitalization?
Immatics N.V.'s market capitalization is approximately $1.3B.
Who is the CEO of Immatics N.V.?
Dr. Harpreet Singh Ph.D. is the chief executive officer of Immatics N.V. (IMTX).
Get the full picture on Immatics N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.